{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gene+expression+study&page=16",
    "query": {
      "intervention": "Gene expression study",
      "page": 16
    },
    "page_size": 10
  },
  "pagination": {
    "page": 16,
    "page_size": 10,
    "total_count": 780,
    "total_pages": 78,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gene+expression+study&page=17&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gene+expression+study&page=15&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T18:19:15.409Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07097792",
      "title": "Concussion Recovery and Support Program",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Brain Concussion",
        "Mild Traumatic Brain Injury",
        "Headache"
      ],
      "interventions": [
        {
          "name": "CRISP (Concussion Recovery and Support Program)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Seattle Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "29 Years",
        "sex": "ALL",
        "summary": "18 Years to 29 Years"
      },
      "enrollment_count": 40,
      "start_date": "2025-10-13",
      "completion_date": "2026-07-31",
      "has_results": false,
      "last_update_posted_date": "2025-11-18",
      "last_synced_at": "2026-10-23T18:19:15.409Z",
      "location_count": 2,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07097792"
    },
    {
      "nct_id": "NCT05627687",
      "title": "Caring Relationships Expression Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Caregiver Burden",
        "Anxiety",
        "Stress"
      ],
      "interventions": [
        {
          "name": "Heart Rate Variability Biofeedback",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Music Listening Control",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Arizona State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 38,
      "start_date": "2021-12-13",
      "completion_date": "2023-07-01",
      "has_results": false,
      "last_update_posted_date": "2024-02-12",
      "last_synced_at": "2026-10-23T18:19:15.409Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05627687"
    },
    {
      "nct_id": "NCT05904639",
      "title": "Decoding Your Diet (DYD)",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Cardiovascular Disease"
      ],
      "interventions": [
        {
          "name": "Decoding Your Diet",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Morehouse School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "40 Years to 70 Years"
      },
      "enrollment_count": 15,
      "start_date": "2023-07",
      "completion_date": "2024-07",
      "has_results": false,
      "last_update_posted_date": "2023-06-18",
      "last_synced_at": "2026-10-23T18:19:15.409Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05904639"
    },
    {
      "nct_id": "NCT01438112",
      "title": "Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Transitional Cell Carcinoma",
        "Bladder Cancer",
        "Carcinoma in Situ",
        "Carcinoma in Situ Concurrent With Papillary Tumors"
      ],
      "interventions": [
        {
          "name": "CG0070 Adenovirus Vector",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Control Arm: Quadruple Choice",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "CG Oncology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2014-03",
      "completion_date": "2016-06",
      "has_results": false,
      "last_update_posted_date": "2021-04-14",
      "last_synced_at": "2026-10-23T18:19:15.409Z",
      "location_count": 7,
      "location_summary": "Phoenix, Arizona • La Jolla, California • Los Angeles, California + 4 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01438112"
    },
    {
      "nct_id": "NCT03334617",
      "title": "Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Danvatirsen",
          "type": "DRUG"
        },
        {
          "name": "Ceralasertib",
          "type": "DRUG"
        },
        {
          "name": "Vistusertib",
          "type": "DRUG"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Oleclumab",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab deruxtecan",
          "type": "DRUG"
        },
        {
          "name": "Cediranib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 528,
      "start_date": "2017-12-18",
      "completion_date": "2026-09-11",
      "has_results": true,
      "last_update_posted_date": "2025-10-27",
      "last_synced_at": "2026-10-23T18:19:15.409Z",
      "location_count": 17,
      "location_summary": "Duarte, California • Fullerton, California • La Jolla, California + 12 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03334617"
    },
    {
      "nct_id": "NCT01280643",
      "title": "Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Metastatic Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "leucovorin calcium",
          "type": "DRUG"
        },
        {
          "name": "oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "irinotecan hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cetuximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "capecitabine",
          "type": "DRUG"
        },
        {
          "name": "mutation analysis",
          "type": "GENETIC"
        },
        {
          "name": "gene expression analysis",
          "type": "GENETIC"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "immunohistochemistry staining method",
          "type": "OTHER"
        },
        {
          "name": "nucleic acid sequencing",
          "type": "GENETIC"
        },
        {
          "name": "protein expression analysis",
          "type": "GENETIC"
        },
        {
          "name": "polymerase chain reaction",
          "type": "GENETIC"
        },
        {
          "name": "DNA analysis",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "GENETIC",
        "OTHER"
      ],
      "sponsor": "Fox Chase Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2010-03",
      "completion_date": "2014-05",
      "has_results": true,
      "last_update_posted_date": "2021-03-15",
      "last_synced_at": "2026-10-23T18:19:15.409Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01280643"
    },
    {
      "nct_id": "NCT00019825",
      "title": "Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the Pleura",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Esophageal Cancer",
        "Lung Cancer",
        "Malignant Mesothelioma",
        "Metastatic Cancer"
      ],
      "interventions": [
        {
          "name": "decitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "1999-10",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2015-04-29",
      "last_synced_at": "2026-10-23T18:19:15.409Z",
      "location_count": 2,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00019825"
    },
    {
      "nct_id": "NCT01716806",
      "title": "A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hodgkin Disease",
        "Peripheral T Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "brentuximab vedotin",
          "type": "DRUG"
        },
        {
          "name": "bendamustine",
          "type": "DRUG"
        },
        {
          "name": "dacarbazine",
          "type": "DRUG"
        },
        {
          "name": "nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seagen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 131,
      "start_date": "2012-10-31",
      "completion_date": "2023-09-12",
      "has_results": true,
      "last_update_posted_date": "2024-06-11",
      "last_synced_at": "2026-10-23T18:19:15.409Z",
      "location_count": 49,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 43 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01716806"
    },
    {
      "nct_id": "NCT03740724",
      "title": "A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Morphea",
        "Scleroderma, Localized",
        "Scleroderma"
      ],
      "interventions": [
        {
          "name": "FCX-013",
          "type": "GENETIC"
        },
        {
          "name": "veledimex",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "DRUG"
      ],
      "sponsor": "Castle Creek Biosciences, LLC.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2019-12-18",
      "completion_date": "2022-04-21",
      "has_results": true,
      "last_update_posted_date": "2024-01-23",
      "last_synced_at": "2026-10-23T18:19:15.409Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03740724"
    },
    {
      "nct_id": "NCT00775424",
      "title": "PENNVAX-B With or Without IL-12 or IL-15 as a DNA Vaccine for HIV Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infection"
      ],
      "interventions": [
        {
          "name": "PENNVAX-B",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GENEVAX IL-12-4532",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PLACEBO",
          "type": "BIOLOGICAL"
        },
        {
          "name": "IL-15 adjuvant",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 38,
      "start_date": "2008-09",
      "completion_date": "2010-06",
      "has_results": false,
      "last_update_posted_date": "2016-08-25",
      "last_synced_at": "2026-10-23T18:19:15.409Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00775424"
    }
  ]
}